EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of anti-B7-1 and anti-B7-2 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease



Effect of anti-B7-1 and anti-B7-2 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease



Journal of Immunology 163(11): 6180-6186



We examined the role of B7-1 and B7-2, costimulatory molecules critical to full activation of T cells, in the development of Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD). Treatment with mAbs to B7-1 resulted in significant suppression of the development of this disease both clinically and histologically. In mice treated with these mAbs, the production of TNF-alpha and IFN-gamma in the spleen cells was decreased. The delayed-type hypersensitivity and T cell proliferative response specific for TMEV were decreased by this treatment. In contrast, treatment with Abs to B7-2, resulted in no effect on TMEV-IDD. These data suggest that B7-1 is critically involved in the pathogenesis of TMEV-IDD and that Abs to B7-1 could be a novel therapeutic approach in the clinical treatment of demyelinating diseases such as human multiple sclerosis.

(PDF 0-2 workdays service: $29.90)

Accession: 017870701

Download citation: RISBibTeXText

PMID: 10570309



Related references

Therapeutic effect of anti-αv integrin mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease. Journal of Neuroimmunology 268(1-2): 25-34, 2014

Suppressive effect on Theiler's murine encephalomyelitis virus-induced demyelinating disease by the administration of anti-IL-12 antibody. Journal of Immunology 161(10): 5586-5593, 1998

Effects of anti-CD70 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease. Brain Research 1317: 236-245, 2010

Ameliorating effects of anti-Dll4 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease. International Immunology 22(9): 729-738, 2011

Anti-adhesion molecule therapy in Theiler's murine encephalomyelitis virus-induced demyelinating disease. International Immunology 9(12): 1837-1847, 1998

Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease. Journal of Neurovirology 12(4): 251-261, 2006

Therapeutic effects of anti-Delta1 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease. Journal of Neuroimmunology 252(1-2): 66-74, 2012

Characterization of theiler's murine encephalomyelitis virus specific delayed type hypersensitivity responses in theiler's murine encephalomyelitis virus induced demyelinating disease correlation with clinical signs. Journal of Immunology 136(3): 920-927, 1986

The effect of pentoxifylline (PTX) on Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. Cellular Immunology 186(2): 140-146, 1998

Effect of the innate immune response on development of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Journal of Neurovirology 20(5): 427-436, 2015

Phosphatidylserine suppresses Theiler's murine encephalomyelitis virus-induced demyelinating disease. Journal of Neuroimmunology 75(1-2): 113-122, 1997

The TIM-3 pathway ameliorates Theiler's murine encephalomyelitis virus-induced demyelinating disease. International Immunology 26(7): 369-381, 2015

Suppression of Theiler's murine encephalomyelitis virus induced demyelinating disease by administration of gangliosides. Journal of Neuroimmunology 64(1): 45-53, 1996